Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) mimetic used for the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. Recent epidemiological studies and clinical trials have suggested that treatment with GLP-1 mimetics may also diminish the risk of cardiovascular disease in diabetic patients. The mechanism responsible for this effect has yet to be determined; however, one possibility is that they might do so by a direct effect on vascular endothelium. Since low grade inflammation of the endothelium is an early event in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), we determined the effects of liraglutide on inflammation in cultured human aortic endothelial cells (HAECs). Liraglutide reduced the inflammatory responses to TNFα and LPS stimulation, as evidenced by both reduced protein expression of the adhesion molecules VCAM-1 and E-Selectin, and THP-1 monocyte adhesion. This was found to result from increased cell Ca2+ and several molecules sensitive to Ca2+ with known anti inflammatory actions in endothelial cells, including CaMKKβ, CaMKI, AMPK, eNOS and CREB. Treatment of the cells with STO-609, a CaMKK inhibitor, diminished both the activation of AMPK, CaMKI and the inhibition of TNFα and LPS-induced monocyte adhesion by liraglutide. Likewise, expression of an shRNA against AMPK nullified the anti-inflammatory effects of liraglutide. The results indicate that liraglutide exerts a strong anti-inflammatory effect on HAECs. They also demonstrate that this is due to its ability to increase intracellular Ca2+ and activate CAMKKβ, which in turn activates AMPK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1 RAs have an anti-inflammatory effect on endothelial vascular cells through a number of molecular mechanisms, including the activation of adenosine monophosphate-activated protein kinase (AMPK) [75].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that GLP-1 and its analogs have anti-inflammatory properties.”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results demonstrate that the anti-inflammatory effects of liraglutide in human aortic endothelial cells is dependent on activation of CAMKKβ and AMPK, which are cAMP/Ca2+ signaling pathways [60].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Liraglutide (100 μM) reduced the mRNA expression of adhesion molecules such as vascular cell adhesion molecule- (VCAM-) 1, ICAM-1, and E-selectin in TNF-α- or LPS-stimulated human aortic endothelial cells and human umbilical vein endothelial cells [60–62].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [60]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Second, GLP-1RAs encourage initiating anti-inflammatory mechanisms such as the AMP-activated protein kinase (AMPK) pathway, which helps suppress inflammation.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010 · cited 1×
“As recently reviewed, TNFa and LPS stimulated monocyte adhesion to endothelial cells are initiating events in the pathogenesis of atherosclerosis [41].”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“The cellular signaling mechanisms stimulated by GLP-1R agonists in pancreatic b-cells are known [25], but whether GLP-1R agonists directly induce signaling in endothelial cells that could be cardioprotective is not clear.”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“It potentiates insulin secretion, blocks glucagon release and increases satiety [1,2], but cannot be used directly as a therapy for Type 2 diabetes due to its short (2 minute) half life.”
BackgroundHawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,665
Woods, A., Dickerson, K., Heath, R., Hong, S.-P., Momcilovic, M., Johnstone, S. R., Carlson, M., & Carling, D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.06.005 · Cited by 1,392 · cited 1×
“STO-609 is a CaMKKa and CaMKKb specific inhibitor that has been used in other studies to inhibit the phosphorylation of AMPK resulting from calcium fluxes [39].”
Creely, S. J., McTernan, P. G., Kusminski, C. M., Fisher, F. M., Da Silva, N. F., Khanolkar, M., Evans, M., Harte, A. L., & Kumar, S. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00302.2006 · Cited by 1,043 · cited 2×
“and LPS [17,18] both of which have been linked to increased cardiovascular disease risk [19] and the induction of inflammatory responses in endothelial cells.”
BackgroundThe Ca2+/Calmodulin-dependent Protein Kinase Kinases Are AMP-activated Protein Kinase Kinases
Hurley, R. L., Anderson, K. A., Franzone, J. M., Kemp, B. E., Means, A. R., & Witters, L. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503824200 · Cited by 1,018 · cited 2×
“There are two primary mechanisms for the activation of AMPK in endothelial cells, one through CaMKKb [53] and the other LKB1 [54].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“It potentiates insulin secretion, blocks glucagon release and increases satiety [1,2], but cannot be used directly as a therapy for Type 2 diabetes due to its short (2 minute) half life.”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“GLP-1 mimetic therapy improved global left ventricular (LV) function in patients with acute myocardial infarction and LV dysfunction after successful reperfusions [56], and ischemia in patients with coronary artery disease [57].”
BackgroundVascular Adhesion Molecules in Atherosclerosis
Galkina, E., & Ley, K. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.149179 · Cited by 803
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“The integrity of endothelial cells was shown to be stabilized by exenatide [158,159].”
BackgroundThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
“which are cAMP/Ca signaling pathways [60].”
AMPK: positive and negative regulation, and its role in whole-body energy homeostasis
Hardie, D. G. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.004 · Cited by 485
“Knocking down axin in liver and cultured cells caused defective AMPK activation, and axin was found to interact with both AMPK and LKB1, although not CaMKKb [22 ].”
BackgroundInfluentialAnti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“30,31 Furthermore, GLP-1RA has demonstrated the ability to reduce the activation of nuclear factor-kappa B (NF-κ B), a crucial inflammation controller, leading to a decrease in the generation of inflammatory agents.”
BackgroundHelmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000615456.97862.30 · Cited by 283
“However, GLP-1(9-36)amide, generated by DPP-4-mediated cleavage of native GLP1, exerts cardioprotective actions in the ischemic mouse heart.”
InfluentialDiNicolantonio, J. J., Bhutani, J., & O'Keefe, J. H. (2015) · Open Heart · doi:10.1136/openhrt-2015-000327 · Cited by 228
“The activation of AMPK also adds to GLP-1’s positive influence on the endothelium.(112) GLP-1 reduces hepatic fatty acid synthesis, increases their oxidation,(113) 114 and GLP-1 agonists have been demonstrated to have favourable effects on rodent models and in humans with non-”
BackgroundSarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
“Incubation of endothelial cells with liraglutide reduced the expression of several inflammatory and pro-inflammatory proteins involved in the atherosclerosis development and progression [154].”
BackgroundSalt, I. P., & Hardie, D. G. (2017) · Circulation Research · doi:10.1161/circresaha.117.309633 · Cited by 187
Zhu, H., Zhang, Y., Shi, Z., Lu, D., Li, T., Ding, Y., Ruan, Y., & Xu, A. (2016) · Scientific Reports · doi:10.1038/srep26859 · Cited by 183
AMPK, metabolism, and vascular function
Rodríguez, C., Muñoz, M., Contreras, C., & Prieto, D. (2021) · The FEBS Journal · doi:10.1111/febs.15863 · Cited by 177
Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 172
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
“CaMKKb phosphorylated AMPK and CaMK1 activated next enzymes, including endothelial nitric oxide synthase (eNOS) and cAMP response element-binding protein (CREB), which contributed to anti-inflammatory effect [106].”
BackgroundMolecular Mechanisms Underlying Ca2+/Calmodulin-Dependent Protein Kinase Kinase Signal Transduction
Tokumitsu, H., & Sakagami, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911025 · Cited by 160
Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137
“Emerging evidence indicates that GLP-1 and its analogs have direct effects on vascular endothelium (6, 15, 22, 24, 29, 31).”
BackgroundInfluentialVinué, Á., Navarro, J., Herrero-Cervera, A., García-Cubas, M., Andrés-Blasco, I., Martínez-Hervás, S., Real, J. T., Ascaso, J. F., & González-Navarro, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4330-3 · Cited by 137
Inflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
“Again emphasizing the interrelation of metabolic and inflammatory disorders, beneficial outcomes have also been observed in cardiovascular disease (67), stroke (68), hepatic diseases (69, 70), nephritis (71), neuro-inflammation (72, 73), rheumatoid arthritis (74), lung inflammation (75), and sepsis (7) (Figure 2).”
BackgroundHypothalamic AMPK and energy balance
López, M. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12996 · Cited by 116
Nauck, M. A., & Quast, D. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645566 · Cited by 112
“The integrity of endothelial cells was shown to be stabilized by exenatide, suggesting further protective effects of GLP-1 receptor stimulation (52, 53).”
BackgroundTong, W., Ju, L., Qiu, M., Xie, Q., Chen, Y., Shen, W., Sun, W., Wang, W., & Tian, J. (2016) · Hepatology Research · doi:10.1111/hepr.12634 · Cited by 113
Jojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105
Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 102
“There is strong evidence indicating GLP-1 has potent anti-inflammatory potentials which may be beneficial against inflammatory responses and reduces the circulating inflammatory mediators leading to an increase in peripheral insulin sensitivity [12, 86-91].”
BackgroundRogliani, P., Calzetta, L., Capuani, B., Facciolo, F., Cazzola, M., Lauro, D., & Matera, M. G. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0311oc · Cited by 99
Fan, L., Cacicedo, J. M., & Ido, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13303 · Cited by 86
Self-citationLiraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
Bruen, R., Curley, S., Kajani, S., Crean, D., O’Reilly, M. E., Lucitt, M. B., Godson, C. G., McGillicuddy, F. C., & Belton, O. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0626-3 · Cited by 81
“It has been shown that liraglutide reduces monocyte adherence to human aortic endothelial cells in response to TNF-alpha and LPS stimulation [42].”
BackgroundEJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?
López, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0927 · Cited by 82
Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation
Luo, X., Hu, Y., He, S., Ye, Q., Lv, Z., Liu, J., & Chen, X. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.07.008 · Cited by 74
Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease
Dou, L., & Jourde‐Chiche, N. (2019) · Toxins · doi:10.3390/toxins11100578 · Cited by 79
“GLP-1RA treatment of cultured endothelial cells reduces TNF-α-induced endothelial inflammation by a mechanism dependent on intracellular Ca2+ and activation of CAMKKβ and AMPK [92].”
BackgroundRibeiro-Silva, J. C., Tavares, C. A. M., & Girardi, A. C. C. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102355 · Cited by 71
Yaribeygi, H., Atkin, S. L., Pirro, M., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27699 · Cited by 72
Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?
López, M., & Tena-Sempere, M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.014 · Cited by 70
Bifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
Insuela, D. B. R., & Carvalho, V. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.015 · Cited by 72
Zhou, J. Y., Poudel, A., Welchko, R., Mekala, N., Chandramani-Shivalingappa, P., Rosca, M. G., & Li, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172594 · Cited by 67
Jansen, T., Kvandová, M., Daiber, A., Stamm, P., Frenis, K., Schulz, E., Münzel, T., & Kröller-Schön, S. (2020) · Antioxidants · doi:10.3390/antiox9060525 · Cited by 68
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
Lg, S., Дігтяр, Н. І., Селіхова, Л. Г., Кайдашева, Е. І., Shlykova, O. A., Vesnina, L. E., & Кайдашев, І. П. (2019) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2019-0003 · Cited by 81
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Liraglutide was found to confer resistance to TNF-α - and liposaccharide-induced inflammation and inhibit monocyte recruitment to the vascular endothelium by lowering VCAM-1 and E-selectin expression in cultured human aortic endothelial cells [131].”
BackgroundAnti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.117152 · Cited by 63
Sottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 84
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
“Pretreatment of HAECs with liraglutide (100 nmol/L, 1 hour) followed by an additional 3 hours of liraglutide exposure attenuated the induction of VCAM-1 and E-selectin by TNF (10 ng/mL) or lipopolysaccharide (2 g/mL) (89).”
MethodMolecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Saad, M. I., Abdelkhalek, T. M., Saleh, M. M., Kamel, M. A. E.-N., Youssef, M., Tawfik, S. H., & Domínguez, H. (2015) · Endocrine · doi:10.1007/s12020-015-0709-4 · Cited by 68
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
Jinnouchi, H., Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Suzuki, T., Miyamoto, F., Kajiwara, K., Matsui, K., & Jinnouchi, T. (2015) · Journal of Diabetes Research · doi:10.1155/2015/706416 · Cited by 55
“Liraglutide has been shown to decrease oxidative stress [22, 23] and inflammation [8, 24] and the suppression of oxidative stress and inflammation might link to the amelioration of insulin resistance.”
BackgroundResultInfluentialXu, X. J., Apovian, C., Hess, D., Carmine, B., Saha, A., & Ruderman, N. (2015) · Diabetes · doi:10.2337/db14-1765 · Cited by 55
“Although not measured in this study, GLP-1 is known to increase significantly after RYGB surgery (20), and it can activate AMPK at least in endothelial cells (21).”
BackgroundSelf-citationZhang, F., Chen, Z., Wu, D., Tian, L., Chen, Q., Ye, Y., Chen, W., Wu, X., Wu, P., Yuan, W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103382 · Cited by 54
“GLP-1 and its analogs have been reported to regulate intracellular calcium homeostasis in many cells, including cardiomyocytes (Hu et al., 2017; Huang et al., 2016), pancreatic beta cells (Leech et al., 1996), endothelial cells (Krasner et al., 2014), etc.”
BackgroundThe alleviating effect and mechanism of GLP-1 on ulcerative colitis
Wang, W., Zhang, C., Zhang, H., Li, L., Fan, T., & Jin, Z. (2023) · Aging · doi:10.18632/aging.204953 · Cited by 62
Fluid Shear Stress–Regulated Vascular Remodeling: Past, Present, and Future
Deng, H., Eichmann, A., & Schwartz, M. A. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322557 · Cited by 61
Bułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., & Okopień, B. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1277-8 · Cited by 55
Ejarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53
Bretón‐Romero, R., Weisbrod, R. M., Feng, B., Holbrook, M., Ko, D., Stathos, M. M., Zhang, J., Fetterman, J. L., & Hamburg, N. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009379 · Cited by 54
Hakon, J., Ruscher, K., Romner, B., & Tomasevic, G. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120074 · Cited by 52
“Liraglutide also reduced the expression of ROS and various adhesion molecules in cultures of human endothelial cells [47,48].”
BackgroundWang, X., Chen, W., Jin, R., Xu, X., Wei, J., Huang, H., Tang, Y., Zou, C., & Chen, T. (2022) · Microbial Biotechnology · doi:10.1111/1751-7915.14196 · Cited by 53
“…produced by distal intestinal mucosal endocrine cells, apart from its effect on glucose metabolism, GLP- 1 has anti- inflammatory and antioxidant effects in cell types associated with atherosclerosis formation, as well as direct cardioprotective effects (Krasner et al., 2014; Shiraki et al., 2012).”
BackgroundTomo, P. D., Lanuti, P., Pietro, N. D., BALDASSARRE, M. P. A., Marchisio, M., Pandolfi, A., Consoli, A., & Formoso, G. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2925 · Cited by 53
“This finding is consistent with the observations by Krasner et al, who demonstrated suppressed THP‐1 monocyte adhesion in human aortic endothelial cells exposed to an inflammatory insult, such as TNF‐α, after Liraglutide treatment.(30) The mitigation of the pro‐atherosclerotic changes we observed in vitro is in keepin…”
ResultGLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
“In animal models and in vitro experiments of sepsis, GLP-1 analogs inhibited TNFα and LPS-induced monocyte adhesion, thereby reducing vascular endothelial injury (Krasner et al., 2014).”
BackgroundMcCarty, M. F., & DiNicolantonio, J. J. (2015) · Open Heart · doi:10.1136/openhrt-2014-000205 · Cited by 52
Wei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 44
“Frontiers in Endocrinology 06 inhibit TNF-a-induced oxidative stress and inflammation in endothelial cells through calcium and AMPK-dependent mechanisms (26, 27), and reduce the occurrence and progression of atherosclerotic plaque formation at an early stage and enhance plaque stability (28).”
BackgroundTargeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 69
“Additionally, GLP-1 receptor agonists demonstrate neuroprotective effects by activating NF-κ B and PI3K/Akt pathways, reducing neuroinflammation through cytokine modulation, and inhibiting TNF α -induced monocyte adhesion while activating AMPK via CaMKK β [148,149].”
Xu, J., Wei, G., Wang, J., Zhu, J., Yu, M., Zeng, X., Wang, H., Xie, W., & Kong, H. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0170-0 · Cited by 49
Gutierrez, A. D., Gao, Z., Hamidi, V., Zhu, L., Saint Andre, K. B., Riggs, K., Ruscheinsky, M., Wang, H., Yu, Y., Miller, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100813 · Cited by 44
“Interestingly, nuclear factor kappa B (NfkB), a key activator of IL-6 expression, is suppressed by GLP1 analogs.(42) We speculate that signaling is mediated by cAMP-response element-binding protein (CREB) known to be downstream of GLP1R and activating IL-6 transcription.”
BackgroundLiraglutide pretreatment attenuates sepsis-induced acute lung injury
Baer, B., Putz, N. D., Riedmann, K. J., Gonski, S. K., Lin, J., Ware, L. B., Toki, S., Peebles, R. S., Cahill, K. N., & Bastarache, J. A. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00041.2023 · Cited by 46
Garczorz, W., Gallego‐Colon, E., Kosowska, A., Kłych‐Ratuszny, A., Woźniak, M., Marcol, W., Niesner, K. J., & Francuz, T. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12317 · Cited by 43
Lambadiari, V., Thymis, J., Kouretas, D., Skaperda, Z., Tekos, F., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2021) · Antioxidants · doi:10.3390/antiox10091379 · Cited by 42
“A mechanism that may confer to the amelioration of oxidative stress by GLP1-RA is reduction of TNF-α-induced oxidative stress and inflammation in endothelial cells and this effect is mediated by a calcium- and AMPK-dependent mechanism [64].”
BackgroundTrevisan, M., Fu, E. L., Szummer, K., Norhammar, A., Lundman, P., Wanner, C., Sjölander, A., Jernberg, T., & Carrero, J. J. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa004 · Cited by 41
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
Sun, H., Zhu, X., Lin, W., Zhou, Y., Cai, W., & Qiu, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478920 · Cited by 44
Tramutola, A., Arena, A., Cini, C., Butterfield, D. A., & Barone, E. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1246183 · Cited by 38
“[158,159], it is possible that the reduction in BBB permeability and brain edema post-TBI could be related to its anti-inflam-”
BackgroundThe Role of Gasotransmitters in Gut Peptide Actions
Verbeure, W., van Goor, H., Mori, H., van Beek, A. P., Tack, J. F., & van Dijk, P. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720703 · Cited by 42
Li, D., Xu, X., Zhang, Y., Zhu, J., Ye, L., Lee, K., & Ma, J. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.051 · Cited by 42
“Because liraglutide can improve insulin resistance [11] and inflammatory response [19,28], it was proposed that decreased blood resistin levels following liraglutide administration could partially account for the beneficial effects of liraglutide on glucose metabolism.”
BackgroundBalogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
“It also induced AMPK activation, via increasing calmodulindependent protein kinase-β activation, in human aortic endothelial cells [61].”
BackgroundThe critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress
Bale, B. F., Doneen, A. L., Leimgruber, P. P., & Vigerust, D. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1042729 · Cited by 41
Tsai, T.-H., Lee, C.-H., Cheng, C.-I., Fang, Y.-N., Chung, S.-Y., Chen, S.-M., Lin, C.-J., Wu, C.-J., Hang, C.-L., & Chen, W.-Y. (2019) · Cells · doi:10.3390/cells8060589 · Cited by 37
Li, N., Zhao, Y., Yue, Y., Chen, L., Yao, Z., & Niu, W. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.095 · Cited by 40
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Liao, P., Yang, D., Liu, D., & Zheng, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485820 · Cited by 35
Shi, M., Wang, J., Xiao, Y., Wang, C., Qiu, Q., Lao, M., Yu, Y., Li, Z., Zhang, H., Ye, Y., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01714 · Cited by 38
Diabetic endothelial microangiopathy and pulmonary dysfunction
Zhang, L., Jiang, F., Xie, Y., Mo, Y., Zhang, X., & Liu, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1073878 · Cited by 37
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“Furthermore, liraglutide treatment for 12 weeks in T2DM patients well controlled on metformin monotherapy resulted in an improvement in both circulating markers of vascular function [asymmetric dimethylarginine, plasminogen activator inhibitor-1 (PAI-1), E-selectin] and retinal microvascular endothelial function (Fors…”
BackgroundInfluentialAnti-inflammatory Property of AMP-activated Protein Kinase
Noor, H. B., Mou, N. A., Salem, L., Shimul, M. F. A., Biswas, S., Akther, R., Khan, S., Raihan, S., Mohib, M. M., & Sagor, M. A. T. (2019) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523018666190830100022 · Cited by 39
Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
Sawada, N., Adachi, K., Nakamura, N., Miyabe, M., Ito, M., Kobayashi, S., Miyajima, S., Suzuki, Y., Kikuchi, T., Mizutani, M., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8843310 · Cited by 37
“Liraglutide inhibited lipopolysaccharide-induced TNF-α expressions in vascular endothelial cells and monocytes [19].”
BackgroundShah, F. A., Mahmud, H., Gallego‐Martin, T., Jurczak, M. J., O'Donnell, C. P., & McVerry, B. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00296 · Cited by 33
Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells
Choung, J.-S., Lee, Y.-S., & Jun, H.-S. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0078 · Cited by 31
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
“It was shown that administration of 100μM liraglutide resulted in a significant reduction in adhesion molecules’ ge e expression [77,78].”
BackgroundInfluentialBattistoni, A., Piras, L., Tartaglia, N., Carrano, F. M., Vitis, C. D., & Barbato, E. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1669685 · Cited by 49
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
“Another study reported a decline in the adhesion of monocytes to cultured aortic endothelial cells treated with liraglutide; liraglutide also reduced the inflammatory response to TNFα and LPS stimulation [75].”
BackgroundLiraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
Chong, L., Liu, Y., He, J. N., Mu, R., Di, Y., Shen, N., Liu, X., Gao, X., Wang, J., Chen, T., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00789 · Cited by 30
Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension
Liu, L., Liu, J., & Huang, Y. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000176 · Cited by 32
“Studies reveal that GLP-1 and its analogues stimulate AMPK phosphorylation resulting in the phosphorylation of its downstream target eNOS (Ser1177) in HUVECs(49) and in human aortic endothelial cells.(64) Furthermore, GLP-1– induced AMPKa/eNOS activation restores EDRs in renal arteries, thus helping to reduce systolic…”
BackgroundCheng, Y., Young, G., Lin, J., Jang, H.-H., Chen, C., Nong, J.-Y., Chen, P., Kuo, C., Kao, S., Liang, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142283 · Cited by 31
“Therefore, our results support previous investigations of the roles of AMPK in response to different stimuli [19].”
ResultGhebrehiwet-Kuflom, J., Mehta, A., Lim, P., Dahle, S. E., & Isseroff, R. R. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.08.045 · Cited by 33
Vascular AMPK as an attractive target in the treatment of vascular complications of obesity
García‐Prieto, C. F., Gil‐Ortega, M., Aránguez, I., Ortiz-Besoain, M., Somoza, B., & Fernández‐Alfonso, M. S. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.02.017 · Cited by 33
Koshibu, M., Mori, Y., Saito, T., Kushima, H., Hiromura, M., Terasaki, M., Takada, M., Fukui, T., & Hirano, T. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00511.2018 · Cited by 27
“However, there is a contradictory report that liraglutide suppresses adhesion of monocytic leukemia THP-1 cells to cultured human aortic endothelial cells via mechanisms that are dependent of AMPK and calcium/calmodulin-dependent protein kinase kinase (26).”
BackgroundHaghbin, H., Gangwani, M. K., Ravi, S. J. K., Perisetti, A., Aziz, M., Goyal, H., Nawras, A., & Sodeman, T. (2020) · Annals of Gastroenterology · doi:10.20524/aog.2020.0550 · Cited by 35
“Liraglutide has been shown to downregulate TNF-α-induced oxidative stress [56] and endothelial inflammation [57].”
BackgroundPotenza, M. A., Nacci, C., Salvia, M. A. D., Sgarra, L., Collino, M., & Montagnani, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.009 · Cited by 27
Chen, X.-M., Zhang, W.-Q., Tian, Y., Wang, L.-F., Chen, C.-C., & Qiu, C.-M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0701-4 · Cited by 25
“First, it has been shown that in cultured human aortic endothelial cells (HAECs), liraglutide reduces the protein expression of VCAM-1 in response to TNFα and LPS stimulation and increases intracellular calcium and cAMP levels, leading to the phosphorylation of AMPK, which is an evolutionarily conserved fuel and stres…”
BackgroundZhang, G., Kim, S., Gu, X., Yu, S. P., & Wei, L. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00446-w · Cited by 28
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
“Significantly, it has been demonstrated that GLP-1 analogues can suppress NF-κB, which is a major activator of IL-6 expression [121].”
Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity
Sardar, M. B., Nadeem, Z. A., & Babar, M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102489 · Cited by 30
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Metadata
- Authors
- Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M.
- Affiliations
- Boston University (US)
- Corresponding author
- Krasner, Nadia M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-16
- Volume
- 9
- Issue
- 5
- Pages
- e97554
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4023984
- OpenAlex
- W2008026539
- Cited by
- 186
- References
- 57
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 13 · 2020: 8 · 2019: 22 · 2018: 11 · 2017: 19 · 2016: 18 · 2015: 15 · 2014: 3
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Heart Association
- National Institutes of Health (NHLBI T32, HL068758)
- National Heart, Lung, and Blood Institute (PO1 HL068758, P01HL068758, HL07969, T32HL007969)
- National Institute of Diabetes and Digestive and Kidney Diseases (R24DK094749)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- liraglutide, GLP-1 receptor agonists, endothelial inflammation, aortic endothelial cells, intracellular calcium, AMPK, CaMKKβ, CaMKI, endothelial nitric oxide synthase, CREB, TNF-α, lipopolysaccharide, monocyte adhesion, VCAM-1, E-selectin, atherosclerotic cardiovascular disease, type 2 diabetes, cardiovascular risk
- MeSH terms
- Liraglutide, Analysis of Variance, Benzimidazoles, Calcium, Cells, Cultured, Endothelium, Vascular, Humans, Immunoenzyme Techniques, Inflammation, Blotting, Western, RNA Interference, RNA, Small Interfering, Endothelial Cells, Glucagon-Like Peptide 1, Naphthalimides, Calcium-Calmodulin-Dependent Protein Kinase Kinase, Incretins, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.